Kara Johnson

3.1k total citations
19 papers, 978 citations indexed

About

Kara Johnson is a scholar working on Hematology, Genetics and Rheumatology. According to data from OpenAlex, Kara Johnson has authored 19 papers receiving a total of 978 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Hematology, 8 papers in Genetics and 7 papers in Rheumatology. Recurrent topics in Kara Johnson's work include Chronic Myeloid Leukemia Treatments (10 papers), Chronic Lymphocytic Leukemia Research (8 papers) and Eosinophilic Disorders and Syndromes (7 papers). Kara Johnson is often cited by papers focused on Chronic Myeloid Leukemia Treatments (10 papers), Chronic Lymphocytic Leukemia Research (8 papers) and Eosinophilic Disorders and Syndromes (7 papers). Kara Johnson collaborates with scholars based in United States, Australia and Singapore. Kara Johnson's co-authors include Brian Druker, Michael W. Deininger, Thomas O’Hare, Stephanie G. Willis, Christopher A. Eide, Heather A. Bradeen, Francis Y. Lee, Paul La Rosée, Amie S. Corbin and Michael O’Dwyer and has published in prestigious journals such as Journal of Biological Chemistry, Blood and PLoS ONE.

In The Last Decade

Kara Johnson

18 papers receiving 953 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Kara Johnson United States	15	607	472	337	313	114	19	978
P. Rae United States	6	984 1.6×	679 1.4×	476 1.4×	412 1.3×	279 2.4×	8	1.4k
Tomasz Sacha Poland	14	466 0.8×	406 0.9×	205 0.6×	175 0.6×	134 1.2×	95	727
Z Estrov United States	15	631 1.0×	330 0.7×	129 0.4×	335 1.1×	287 2.5×	17	1.1k
Lisa Hopcroft United Kingdom	13	489 0.8×	293 0.6×	97 0.3×	342 1.1×	141 1.2×	23	814
Pascale Cony‐Makhoul France	24	1.3k 2.1×	864 1.8×	502 1.5×	257 0.8×	318 2.8×	76	1.5k
Sven‐Aage Killmann Denmark	17	432 0.7×	210 0.4×	136 0.4×	284 0.9×	127 1.1×	39	848
Muhammad Shurafa United States	12	420 0.7×	262 0.6×	46 0.1×	271 0.9×	319 2.8×	29	912
Naresh Punwani United States	12	268 0.4×	288 0.6×	230 0.7×	178 0.6×	241 2.1×	17	803
P. Brent Ferrell United States	17	296 0.5×	126 0.3×	110 0.3×	325 1.0×	264 2.3×	49	1.1k
Abelardo Bárez Spain	17	513 0.8×	309 0.7×	42 0.1×	386 1.2×	226 2.0×	42	918

Countries citing papers authored by Kara Johnson

Since Specialization

Citations

This map shows the geographic impact of Kara Johnson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kara Johnson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kara Johnson more than expected).

Fields of papers citing papers by Kara Johnson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kara Johnson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kara Johnson. The network helps show where Kara Johnson may publish in the future.

Co-authorship network of co-authors of Kara Johnson

This figure shows the co-authorship network connecting the top 25 collaborators of Kara Johnson. A scholar is included among the top collaborators of Kara Johnson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kara Johnson. Kara Johnson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

Eide, Christopher A., Stephen E. Kurtz, Nicola Long, et al.. (2026). DDX41-Mutated AML: A Case Report and Perspectives. JCO Precision Oncology. 10(1). e2500992–e2500992.

Johnson, Kara, et al.. (2024). Local Food System Approaches to Address Food and Nutrition Security among Low-Income Populations: A Systematic Review. Advances in Nutrition. 15(4). 100156–100156. 14 indexed citations

Sun, Qiao‐Yang, Ling‐Wen Ding, Kara Johnson, et al.. (2019). SOX7 regulates MAPK/ERK-BIM mediated apoptosis in cancer cells. Oncogene. 38(34). 6196–6210. 38 indexed citations

Niewoehner, Dennis E., Kara Johnson, Chris H. Wendt, et al.. (2016). High-dose oral N-acetylcysteine fails to improve respiratory health status in patients with chronic obstructive pulmonary disease and chronic bronchitis: a randomized, placebo-controlled trial. International Journal of COPD. 11. 799–799. 32 indexed citations

Johnson, Kara, et al.. (2016). Order Set to Improve the Care of Patients Hospitalized for an Exacerbation of Chronic Obstructive Pulmonary Disease. Annals of the American Thoracic Society. 13(6). 811–815. 20 indexed citations

Chang, Bill H., Kara Johnson, Dorian LaTocha, et al.. (2015). YM155 potently kills acute lymphoblastic leukemia cells through activation of the DNA damage pathway. Journal of Hematology & Oncology. 8(1). 39–39. 31 indexed citations

O’Hare, Thomas, Christopher A. Eide, Anupriya Agarwal, et al.. (2013). Threshold Levels of ABL Tyrosine Kinase Inhibitors Retained in Chronic Myeloid Leukemia Cells Determine Their Commitment to Apoptosis. Cancer Research. 73(11). 3356–3370. 23 indexed citations

Johnson, Kara, Ian J. Griswold, Thomas O’Hare, et al.. (2009). A BCR-ABL Mutant Lacking Direct Binding Sites for the GRB2, CBL and CRKL Adapter Proteins Fails to Induce Leukemia in Mice. PLoS ONE. 4(10). e7439–e7439. 21 indexed citations

Bradeen, Heather A., Christopher A. Eide, Thomas O’Hare, et al.. (2006). Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)–based mutagenesis screen: high efficacy of drug combinations. Blood. 108(7). 2332–2338. 317 indexed citations

10.

MacPartlin, Mary, Thomas O’Hare, Thomas G.P. Bumm, et al.. (2006). Kinase Domain Mutants of Bcr-Abl Exhibit Altered Transformation Potency, Kinase Activity, and Substrate Utilization, Irrespective of Sensitivity to Imatinib.. Blood. 108(11). 4796–4796. 2 indexed citations

11.

Griswold, Ian J., Mary MacPartlin, Thomas G.P. Bumm, et al.. (2006). Kinase Domain Mutants of Bcr-Abl Exhibit Altered Transformation Potency, Kinase Activity, and Substrate Utilization, Irrespective of Sensitivity to Imatinib. Molecular and Cellular Biology. 26(16). 6082–6093. 152 indexed citations

12.

Tseng, Ping‐Hui, Jiuxiang Zhu, Kuen‐Feng Chen, et al.. (2005). Synergistic interactions between imatinib mesylate and the novel phosphoinositide-dependent kinase-1 inhibitor OSU-03012 in overcoming imatinib mesylate resistance. Blood. 105(10). 4021–4027. 52 indexed citations

13.

Gaston, Isabelle, Kara Johnson, Tsukasa Oda, et al.. (2004). Coexistence of phosphotyrosine-dependent and -independent interactions between Cbl and Bcr-Abl. Experimental Hematology. 32(1). 113–121. 7 indexed citations

14.

Rosée, Paul La, Kara Johnson, Amie S. Corbin, et al.. (2003). In vitro efficacy of combined treatment depends on the underlying mechanism of resistance in imatinib-resistant Bcr-Abl–positive cell lines. Blood. 103(1). 208–215. 82 indexed citations

15.

Rosée, Paul La, Kara Johnson, Michael O’Dwyer, & Brian Druker. (2002). In vitro studies of the combination of imatinib mesylate (Gleevec) and arsenic trioxide (Trisenox) in chronic myelogenous leukemia. Experimental Hematology. 30(7). 729–737. 80 indexed citations

16.

Bhat, Arun, Kara Johnson, Tsukasa Oda, Amie S. Corbin, & Brian Druker. (1998). Interactions of p62 with p210 and Bcr-Abl-associated Proteins. Journal of Biological Chemistry. 273(48). 32360–32368. 29 indexed citations

17.

Comstock, Kenine E., et al.. (1993). Isolation and analysis of the gene and cDNA for a human Mu class glutathione S-transferase, GSTM4. Journal of Biological Chemistry. 268(23). 16958–16965. 45 indexed citations

18.

Sanderson, Barbara J.S., Kara Johnson, W. David Henner, & T R Skopek. (1991). Dose‐dependent cytotoxic and mutagenic effects of antineoplastic alkylating agents on human lymphoblastoid cells. Environmental and Molecular Mutagenesis. 17(4). 238–243. 17 indexed citations

19.

Monk, Barry, et al.. (1987). Efficacy of low-dose cyproterone acetate compared with minocycline in the treatment of acne vulgaris. Clinical and Experimental Dermatology. 12(5). 319–322. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact